CureVac’s CVGBM Brain Cancer Vaccine Trial Reaches Completion: What It Means for CVAC Investors
Curevac N.V. (CVAC) announced an update on their ongoing clinical study.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The Phase 1 study “A Phase 1 Dose-Finding Study to Evaluate Safety and Tolerability of CVGBM in Patients With Surgically Resected Glioblastoma or Astrocytoma With a Molecular Signature of Unmethylated Glioblastoma” tests CureVac’s CVGBM cancer vaccine in adults with high risk brain tumors. It aims to find a safe dose and early safety signals in a setting with few effective options, which matters for long term value in CVAC.
The treatment is CVGBM, an mRNA based cancer vaccine given as a muscle injection after surgery and radiation, with or without chemotherapy. The vaccine is designed to train the immune system to recognize and attack glioblastoma cells and related astrocytoma cells and is given in a series of seven shots, with the option to continue for up to one year.
The study uses an interventional design with patients assigned to dose levels in sequence, not by randomization. It is open label, so doctors and patients know the dose given, and the main goal is treatment focused safety and tolerability, not direct comparison with other drugs.
The trial was first submitted in June 2023, marking the formal launch of the program in this indication. According to the latest update filed on February 16, 2026, the study is listed as completed, which means primary data collection on safety and dosing has finished and the sponsor is now able to analyze and prepare disclosures.
The dose escalation stage finished enrollment around February 2024 and a planned expansion stage was expected to start in mid 2024, adding about 20 more patients at the selected dose. While top line results are not yet posted, completion of a first in human cancer vaccine study is a key derisking step for CureVac’s broader oncology pipeline and platform.
For investors, a completed early stage trial in glioblastoma modestly improves the risk profile of CVAC by showing the company can move an mRNA cancer asset through complex brain tumor testing. Near term stock moves will depend on the eventual safety and early response signals, but the update may support sentiment versus peers in mRNA oncology such as BioNTech and Moderna, which are also pushing into solid tumors.
If follow up data show acceptable safety and even limited signs of tumor control in this hard to treat population, CureVac could see renewed interest after past setbacks in vaccines, potentially narrowing its valuation gap to larger mRNA players. The study is now completed and recently updated, with further details available on the ClinicalTrials portal.
To learn more about CVAC’s potential, visit the Curevac N.V. drug pipeline page.
